Ctrl

K

Oritavancin

Class
Antibiotics
Subclass
Glycopeptides
Generic name
Oritavancin
Brand names
Kimyrsa®
Common formulations
Powder for parenteral solution
Dosage and administration
Adults patients
Treatment of SSTIs
•
1,200 mg IV once
Indications for use
Labeled indications
Adults
•
Treatment of SSTIs
Safety risks
Contraindications
Known oritavancin hypersensitivity
Warnings and precautions
Coagulopathy
•
Use caution with concomitant anticoagulant therapy.
Pseudomembranous colitis
•
Use caution presenting with diarrhea after antibacterial use.
Specific populations
Renal impairment
eGFR 20-50 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
eGFR 10-20 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
eGFR < 10 mL/min/1.73 m²
•
Use with caution.
Renal replacement therapy
Continuous renal replacement
•
Use acceptable. No dose adjustment required.
Intermittent hemodialysis
•
Use with caution. Dose as in eGFR < 10 mL/min/1.73 m².
Peritoneal dialysis
•
Use with caution. Dose as in eGFR < 10 mL/min/1.73 m².
Hepatic impairment
Child-Pugh A (mild)
•
Use acceptable. No dose adjustment required.
Child-Pugh B (moderate)
•
Use acceptable. No dose adjustment required.
Child-Pugh C (severe)
•
No guidance available.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Use only if benefits outweigh potential risks.
Breastfeeding
Acceptable for use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Common 1-10%
•
Allergic reactions, angioedema, erythema multiforme, osteomyelitis, ⊕ direct Coombs test, diarrhea, dizziness, generalized pruritus, headache, injection site reactions, nausea, skin rash, vomiting, skin abscess, tachycardia, urticaria
Unknown frequency
•
Clostridioides difficile infection, cellulitis, ↑ INR, ↑ plasma D-dimer, ↑PT, ↑PTT, bleeding
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource